Managing Pain and Treating Bone Metastases in Prostate Cancer

The ALSYMPCA phase III clinical trial, recently published, demonstrated that radium-223 dichloride was well-tolerated and resulted in an improvement in overall survival by 3.6 months compared with placebo.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news